Galectin Therapeutics Inc. (GALT)

3,3850 -0,0850 (-2,45%) Ab 02:42PM EDT. Markt geöffnet.

Galectin Therapeutics Inc.

4960 Peachtree Industrial Boulevard
Suite 240
Norcross, GA 30071
United States
(678) 620-3186
https://galectintherapeutics.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 28

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Joel Lewis	President, CEO & Director	907,72k	N/A	1970
Mr. Jack W. Callicutt CPA	CFO, Treasurer & Corporate Secretary	521,47k	N/A	1967
Dr. Pol F. Boudes M.D., Ph.D.	Chief Medical Officer	730,33k	N/A	1957
Robert Tritt	General Counsel	N/A	N/A	N/A
Mr. Jeff Katstra	Head of CMC & Pharmaceutical Development	N/A	N/A	N/A
Ms. Beth Knowles	Executive Assistant & Officer Manager	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Corporate Governance

Galectin Therapeutics Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.